Abstract
Liquid biopsy, especially circulating tumor DNA (ctDNA) has demonstrated its capability in the detection of genomic alterations. Our large-scale study comparing ctDNA-genotyping versus tissue-genotyping studies for trial enrollment demonstrated that ctDNA genotyping has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Based on the utility of ctDNA genotyping, we are conducting an umbrella, basket project targeting rare fractions of patients with advanced solid malignancies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
